Prostate cancer in an elderly patient with a history of comorbidities

• Authors: Adriana Stryczyńska-Mirocha , Martyna Mirocha

Abstracts

EN

Prostate cancer is the most common cancer in men in Poland. The choice of treatment method depends on many factors, including the stage of the disease, the patient's age, life expectancy, the presence of comorbidities and the general condition of the patient. Hormone therapy is one of the basic methods of prostate cancer treatment, both in adjuvant and palliative treatment. Castration-resistant prostate cancer is an incurable disease. However, the introduction of new hormonal drugs to therapy significantly extended the survival time of patients with relatively low harmfulness of therapy.

Keywords

EN

prostate cancer; hormone therapy; nmCRPC; apalutamide

• Publisher: Medical Education
• Journal: OncoReview
• Year: 2023
• Volume: 13
• Issue: 1
• Pages: 3-5

Dates

published

2023

Contributors

author

Adriana Stryczyńska-Mirocha

• Katowice Cancer Center, Oncology Ward D, One-Day Chemotherapy Ward, Oncology Clinic

author

Martyna Mirocha

• Regional Blood Donation and Blood Treatment Center in Krakow

References

• Didkowska J, Wojciechowska U, Olasek P et al. Cancer in Poland in 2019. Ministry of Health, Warsaw 2021.
• Parker C, Castro E, Fizazi K et al. Prostate cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2020; 31(9): 1119-34. http://doi.org/10.1016/j.annonc.2020.06.011.
• Shore ND, Morgans AK, Ryan CJ. Resetting the Bar of Castration Resistance - Understanding Androgen Dynamics in Therapy Resistance and Treatment Choice in Prostate Cancer. Clin Genitourin Cancer. 2021; 19(3): 199-207. http://doi.org/10.1016/j.clgc.2020.08.008.
• Mottet N, Cornford P, Van den Bergh RCN et al. EAU-EANM-ESTRO-ESUR-ISUP-SIOG Guidelines on prostate cancer, Limited text update March 2022. European Association of Urology. 2022.
• Vidal N, Rivas Gomez J, Fernández L et al. The past, present, and future of non-metastatic castration-resistant prostate cancer (nmCRPC): a narrative review. Precis Cancer Med. 2022; 5: 14. http://doi.org/10.21037/pcm-21-34.
• Parker C, Castro E, Fizazi K et al. Prostate cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2020; 31(9): 1119-34. http://doi.org/10.1016/j.annonc.2020.06.011.
• Mori K, Mostafaei H, Pradere B et al. Apalutamide, enzalutamide, and darolutamide for non-metastatic castration-resistant prostate cancer: a systematic review and network meta-analysis. Int J Clin Oncol. 2020; 25(11): 1892-900. http://doi.org/10.1007/s10147-020-01777-9.
• Smith MR, Saad F, Chowdhury S et al. Apalutamide Treatment and Metastasis-free Survival in Prostate Cancer. N Engl J Med. 2018; 378(15): 1408-18. http://doi.org/10.1056/NEJMoa1715546.

Identifiers

DOI

10.24292/01.OR.131310323

Biblioteka Nauki

22676694